Mobilization of peripheral-blood stem cells by concurrent administration of daniplestim and granulocyte colony-stimulating factor in patients with breast cancer or lymphoma

Journal of Clinical Oncology

Volumn 18, Issue 14, 2000, Pages 2762-2771

  DiPersio, John F ^a   Schuster, Michael W ^a   Abboud, Camille N ^a   Winter, Jane N ^a   Santos, Vicki R ^a   Collins, Denise M ^a   Sherman, Jeffrey W ^a   Baum, Charles M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DANIPLESTIM; INTERLEUKIN 3 RECEPTOR AGONIST; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERANCE; FEVER; HEADACHE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; LYMPHOMA; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RIGOR;

EID: 0033911336     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.14.2762     Document Type: Article

References (51)

1. Shpall EJ, Cagnoni PJ, Bearman SI, et al: Peripheral blood stem cells for autografting. Ann Rev Med 48:241-251, 1997
2. Bensinger W, Appelbaum F, Rowley S, et al: Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 13:2547-2555, 1995
3. Huhn RD, Yurkow EJ, Tushinski R, et al: Recombinant human interleukin-3 (rhIL-3) enhances the mobilization of peripheral blood progenitor cells by recombinant human granulocyte colony-stimulating factor (rhG-CSF) in normal volunteers. Exp Hematol 24:839-847, 1996
4. Donahue RE, Seehra J, Metzger M, et al: Human IL-3 and GM-CSF act synergistically in stimulating hematopoiesis in primates. Science 241:1820-1823, 1988
5. Ottmann OG, Ganser A, Seipelt G, et al: Effects of recombinant human interleukin-3 on human hematopoietic progenitor and precursor cells in vivo. Blood 76:1494-1502, 1990
6. Wognum AW, Visser TP, de Jong MO, et al: Differential expression of receptors for interleukin-3 on subsets of CD34-expressing hematopoietic cells of rhesus monkeys. Blood 86:581-591, 1995
7. Bociek RG, Armitage JO: Hematopoietic growth factors. CA Cancer J Clin 46:165-184, 1996
8. Biesma B, Willemse PHB, Mulder NH, et al: Effects of interleukin-3 after chemotherapy for advanced ovarian cancer. Blood 80:1141-1148, 1992
9. Kurimoto Y, de Weck AL, Dahinden CA: Interleukin 3-dependent mediator release in basophils triggered by C5a. J Exp Med 170:467-479, 1989
10. Mayer P, Valent P, Schmidt G, et al: The in vivo effects of recombinant human interleukin-3: Demonstration of basophil differentiation factor, histamine-producing activity, and priming of GM-CSF-responsive progenitors in nonhuman primates. Blood 74:613-621, 1989
11. Thomas JW, Baum CM, Hood F, et al: Potent interleukin 3 receptor agonist with selectively enhanced hematopoietic activity relative to recombinant human interleukin 3. Proc Natl Acad Sci U S A 92:3779-3783, 1995
12. Fleming WH, Lankford-Turner P, Turner CW, et al: Administration of daniplestim and granulocyte colony-stimulating factor for the mobilization of hematopoietic progenitor cells in nonhuman primates. Biol Blood Marrow Transplant 5:8-14, 1999
13. Southwest Oncology Group: The Southwest Oncology Group Toxicity Criteria. San Antonio, TX, Southwest Oncology Group, Dec 15, 1994 (memorandum)
14. + hematopoietic stem cells for reconstitution following myeloablative therapy. Cytometry 16:74-79, 1994
15. + cell determination by flow cytometry. J Hematother 5:213-226, 1996
16. Loken MR, Civin CI: Laboratory assessment of lymphohematopoietic progenitor and stem cells, in Smith DA, Sacher RA (eds): Peripheral Blood Stem Cells. Bethesda, MD, American Association of Blood Banks, 1993, pp 19-31
17. Loken MR: Peripheral blood stem cell quantification. Cytometry Forum 5:1-4, April 1994
18. Henon PR, Liang H, Beck-Wirth G, et al: Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants. Bone Marrow Transplant 9:285-291, 1992
19. To LB, Roberts MM, Haylock DN, et al: Comparison of hematopoietic recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants, and allogeneic bone marrow transplants. Bone Marrow Transplant 9:277-284, 1992
20. Ager S, Scott MA, Mahendra P, et al: Peripheral blood stem cell transplantation after high-dose chemotherapy in patients with malignant lymphoma: A retrospective comparison with autologous bone marrow transplantation. Bone Marrow Transplant 16:79-83, 1995
21. Schmitz N, Linch DC, Dreger P, et al: Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 347:353-357, 1996
22. Ross AA, Cooper BW, Lazarus HM, et al: Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 82:2605-2610, 1993
23. Miyamato T, Nagafuji K, Harada M, et al: Qualitative analysis of AML1/ETO transcripts in peripheral blood stem cell harvests from patients with t(8;21) acute myelogenous leukemia. Br J Haematol 91:132-138, 1995
24. Passos-Coelho JL, Ross AA, Moss TJ, et al: Absence of breast cancer cells in a single-day peripheral blood progenitor cell collection after priming with cyclophosphamide and granulocyte-macrophage colony-stimulating factor. Blood 85:1138-1143, 1995
25. Henry JM, Sykes PJ, Brisco MJ, et al: Comparison of myeloma cell contamination of bone marrow and peripheral blood stem cell harvests. Br J Haematol 92:614-619, 1996
26. Tarella C, Ferrero D, Bregni M, et al: Peripheral blood expansion of early progenitor cells after high-dose cyclophosphamide and rhGM-CSF. Eur J Cancer 27:22-27, 1991
27. Ravagnani F, Siena S, Bregni M, et al: Large-scale collection of circulating hematopoietic progenitors in cancer patients treated with high-dose cyclophosphamide and recombinant human GM-CSF. Eur J Cancer 26:562-564, 1990
28. Demirer T, Buckner CD, Bensinger WI: Optimization of peripheral blood stem cell mobilization. Stem Cells 14:106-116, 1996
29. Moskowitz CH, Stiff P, Gordon MS, et al: Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients: Results of a phase I/II trial. Blood 89:3136-3147, 1997
30. Glaspy JA, Shpall EJ, LeMaistre CF, et al: Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood 90:2939-2951, 1997
31. Basser RL, Bikto L, Begley G, et al: Rapid hematopoietic recovery after multicycle high-dose chemotherapy: Enhancement of filgrastim-induced progenitor-cell mobilization by recombinant human stem-cell factor. J Clin Oncol 16:1899-1908, 1998
32. - cells cultured with interleukin-3, granulocyte colony-stimulating factor, or granulocyte-macrophage colony-stimulating factor. Blood 77:2316-2321, 1991
33. Tricot G, Jagannath S, Vesole D, et al: Peripheral blood stem cell transplants for multiple myeloma: Identification of favorable variables for rapid engraftment in 225 patients. Blood 85:588-596, 1995
34. Zimmerman TM, Lee WJ, Bender JG, et al: Quantitative CD34 analysis may be used to guide peripheral blood stem cell harvests. Bone Marrow Transplant 9:439-444, 1995
35. Morton J, Morton A, Bird R, et al: Predictors for optimal mobilisation and subsequent engraftment of PBPCs following intermediate dose cyclophosphamide and G-CSF. Blood 86:408a, 1996 (suppl 1) (abstr 1619)
36. Haynes AP, Hunter AE, McQuaker G, et al: Engraftment characteristics of peripheral blood stem cells mobilised with cyclophosphamide and delayed addition of G-CSF. Br J Haematol 89:24, 1995 (suppl 1) (abstr 87)
37. Haas R, Möhle R, Frühauf S, et al: Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 83:3787-3794, 1994
38. Schwartzberg L, Birch R, Blanco R, et al: Rapid and sustained hematopoietic reconstitution by peripheral blood stem cell infusion alone following high-dose chemotherapy. Bone Marrow Transplant 11:369-374, 1993
39. Schwella N, Beyer J, Schwaner I, et al: Impact of preleukapheresis cell counts on collection results and correlation of progenitor-cell dose with engraftment after high-dose chemotherapy in patients with germ cell cancer. J Clin Oncol 14:1114-1121, 1996
40. Bensinger WI, Longin K, Appelbaum F, et al: Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): An analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 87:825-831, 1994
41. + cell dose in engraftment kinetics. Bone Marrow Transplant 18:699-703, 1996
42. + cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 19:303-310, 1997
43. Weaver CH, Hazelton B, Birch R, et al: An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 86:3961-3969, 1995
44. Passos-Coelho JL, Braine HG, Davis JM, et al: Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization. J Clin Oncol 13:705-714, 1995
45. van der Wall E, Richel DJ, Holtkamp MJ, et al: Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: Effect of graft size. Ann Oncol 5:795-802, 1994
46. Chabannon C, Le Coroller A-G, Faucher C, et al: Patient condition affects the collection of peripheral blood progenitors after priming with recombinant granulocyte colony-stimulating factor. J Hematother 4:171-179, 1995
47. Prince HM, Imrie K, Sutherland DR, et al: Peripheral blood progenitor cell collections in multiple myeloma: Predictors and management of inadequate collections. Br J Haematol 93:142-145, 1996
48. Nademanee A, Sniecinski I, Schmidt GM, et al: High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. J Clin Oncol 12:2176-2186, 1994
49. Crawford J, Lau D, Erwin R, et al: A phase I trial of recombinant methionyl human stem cell factor (SCF) in patients (pts) with advanced non-small cell lung carcinoma (NSCLC). Proc Am Soc Clin Oncol 12:135, 1993 (abstr 338)
50. Demetri G, Costa J, Hayes D, et al: A phase I trial of recombinant methionyl human stem cell factor (SCF) in patients with advanced breast carcinoma pre- and post-chemotherapy (chemo) with cyclophosphamide (C) and doxorubicin (A). Proc Am Soc Clin Oncol 12:142, 1993 (abstr 367)
51. Costa JJ, Demetri GD, Harrist TJ, et al: Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med 183:2681-2686, 1996